Sinovac Says Its COVID-19 Vaccine More Effective With Longer Dosing Interval

China’s Sinovac Biotech said on Monday (January 18) that a clinical trial in Brazil showed its COVID-19 vaccine was almost 20 percentage points more effective in a small sub-group of patients who received their two doses longer apart. The protection rate for 1,394 participants who received doses of either CoronaVac or placebo three weeks apart was nearly 70 per cent, a Sinovac spokesman said. Brazilian researchers announced last week that the vaccine’s overall efficacy was 50.4 per cent based on results from more than 9,000 volunteers, most of whom received doses 14 days apart, as outlined in the trial protocol.

Also Read:  Better To Take COVID-19 Vaccine Doses In A Gap Of 6-8 Weeks, Says Dr Suresh Jadhav Of Serum Institute of India

The spokesman said a small number of participants received their second shot late due to a various reasons, without elaborating.

The dosing interval for COVID-19 vaccines has become a hot topic of debate among scientists, regulators and governments.

UK regulators have said a COVID-19 vaccine from AstraZeneca and Oxford University is more effective when there is a longer gap between doses than initially envisaged.

Also Read: Health And Frontline Workers Take The First Jab Of COVID-19 Vaccine, Feel ‘Safe And Proud’

Britain has also decided to allow a longer gap between doses of a COVID-19 vaccine from Pfizer and BioNTech, even though the companies say they only have efficacy data for a shorter period between shots.

The Sinovac spokesman cautioned the robustness of the data from the sub-group was weaker than the 50 per cent result, which is based on the combined data of those receiving doses two or three weeks apart.

While Sinovac’s researchers had said early stage trials showed a four-week interval induced the stronger antibody response than two weeks, this is the first time the company has released efficacy data from a Phase III trial with dosing patterns that differ from its trial protocol.

Sinovac has yet to release global results of its Phase III trials, but its COVID-19 vaccine has been approved for emergency use in several countries, including Brazil, Indonesia and Turkey.

Also Read: Coronavirus Explainer: What Are Adverse Events Post COVID-19 Immunisation

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.